Last reviewed: June 10, 2026 Last updated: June 10, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Patients with T2DM, persons at risk for AD, had a significantly lower associated risk of AD after administered exenatide, liraglutide and dulaglutide ( Conclusion Increasing evidence suggests that anti-diabetes medicine, GLP-1R agonists, have multiple neuroprotective mechanisms in AD models, such as anti-inflammation, anti-oxidative stress, reducing A aggregation/deposition and tau protein hyperphosphorylation, reducing neuronal apoptosis and neurotoxicity, increasing cell proliferation and neurogenesis, increasing synaptic plasticity, and other beneficial effects
If you live with type 1 diabetes, chances are you've heard about GLP-1 medications Ozempic, Wegovy, Mounjaro mostly in the context of weight loss or type 2 diabetes
Zo werkt Tanja nu samen met Stichting Expertisecentrum Oefenen.nl aan heel korte online mini-lesjes die mensen helpen bij alledaagse vraagstukken die spelen op de werkvloer
Insurers may use prior authorization - or advance approval - to ensure that Wegovy is being used for a medically accepted indication, CMS said
